# VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
Canonical URL: https://biopharmsignal.com/news/MXCT/vectorbuilder-partners-with-maxcyter-to-advance-clinical-grade-cell-engineering
Ticker: MXCT
Company: MaxCyte
Source: MaxCyte
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.maxcyte.com
## Summary

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a

## Article Body
The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a
## Recent Company News
- 2026-06-25 13:46 EST — [VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering](https://biopharmsignal.com/news/MXCT/vectorbuilder-partners-with-maxcyter-to-advance-clinical-grade-cell-engineering) — Source: MaxCyte
- 2026-06-25 13:46 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte
- 2026-06-25 13:46 EST — [MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-preliminary-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance) — Source: MaxCyte
- 2026-06-25 13:46 EST — [MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance) — Source: MaxCyte
- 2026-06-25 13:46 EST — [MaxCyte Announces Planned CFO Transition in 2026](https://biopharmsignal.com/news/MXCT/maxcyte-announces-planned-cfo-transition-in-2026) — Source: MaxCyte
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)